233 results on '"Robson, Joanna C."'
Search Results
2. Consensus of the definitions of the OMERACT glucocorticoid impact core domain set for people with rheumatic and musculoskeletal diseases
3. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial
4. Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study
5. Patient-reported outcomes in vasculitis
6. Qualitative interview study of rheumatology patients’ experiences of COVID-19 shielding to explore the physical and psychological impact and identify associated support needs
7. Patient Perceptions of Physical Activity After a Diagnosis of Giant Cell Arteritis: Analysis of Multinational Qualitative Data
8. Patient reported outcomes in systemic vasculitis
9. Nurse‐led care for people with early rheumatoid arthritis: Interview study with thematic analysis
10. Validation of a new glucocorticoid-specific Patient-Reported Outcome Questionnaire (the Steroid PRO)
11. The Patientsʼ Perspective of Important Glucocorticoid Effects: A Nominal Group Study Among Patients With Systemic Lupus Erythematosus and Myositis
12. The impact of treatment with avacopan on health-related quality of life in antineutrophil cytoplasmic antibody-associated vasculitis: a post-hoc analysis of data from the ADVOCATE trial
13. Long-Term Outcome of ANCA-Associated Systemic Vasculitis
14. Validation of a new glucocorticoid-specific Patient-Reported Outcome Questionnaire (the Steroid PRO).
15. Jaw claudication and jaw stiffness in giant cell arteritis: secondary analysis of a qualitative research dataset.
16. Association of the AAV-PRO questionnaire with established outcome measures in AAV.
17. Validation of a patient-reported outcome measure for giant cell arteritis.
18. Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis
19. Validation of a patient-reported outcome measure for giant cell arteritis
20. Association of the ANCA-associated vasculitis (AAV) patient-reported outcome (AAV-PRO) questionnaire with established outcome measures in AAV
21. Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study
22. OA42 Patient experiences of managing their rare rheumatic disease
23. E038 A common measure of the impact of glucocorticoids in patients with inflammatory and autoimmune conditions - the Steroid PRO: A cross-cultural validation study with Rasch models
24. Assessing glucocorticoid toxicity: are the measures sensitive enough?
25. Measuring the impact of steroid therapy on health-related quality of life in patients with rheumatic diseases: international development of a glucocorticoid treatment-specific patient-reported outcome measure
26. Reply to three letters‐Betrains‐Castaneda‐Hemmig for AR‐22‐0212.R1 and AR‐22‐0213.R1
27. Health professionals' perspectives on psychological distress and meeting patients' support needs in rheumatology care settings: A qualitative study
28. 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis
29. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis
30. ANCA Associated Vasculitis Subtypes: Response [Response to Letter]
31. Reply
32. ANCA Associated Vasculitis Subtypes: Response [Response to Letter]
33. ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives
34. Reply.
35. OA23 Patient-reported outcome measure for giant cell arteritis: cross-sectional validation study
36. P301 Patient reported outcome measure for giant cell arteritis: clinical testing
37. P092 Patients’ perceptions of glucocorticoid therapy impact on health-related quality of life during treatment for rheumatic diseases: international development of a treatment-specific patient-reported outcome measure (the Steroid PRO)
38. P293 Tocilizumab for refractory or relapsing giant cell arteritis: audit data from the Bristol and Bath regional multidisciplinary meetings 2018-2021
39. ANCA Associated Vasculitis Subtypes: Recent Insights and Future Perspectives
40. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis
41. Response to: Correspondence on ‘2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis’ by Joanna C Robson et al and ‘2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis’ by Ravi Suppiah et al
42. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis
43. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis
44. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis
45. Comment on: Benchmarking tocilizumab use for giant cell arteritis
46. Correspondence on 'EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update'.
47. Patient reported outcomes in systemic vasculitis
48. The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK
49. 2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis.
50. 2022 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.